Cipmolnu® Molnupiravir Capsules

Molnupiravir 200mg

USD $86.00 (EUR €90.73)

Brand:Cipla

Cipmolnu® Molnupiravir 200mg Capsule (Lagevrio Generic) is the first oral antiviral medication that helps treat mild to moderate COVID-19 in adults. It prevents the virus from multiplying, thereby reducing viral load and disease severity. The drug received emergency use approval from Indian drug regulatory authorities on December 28, 2021.

Cipmolnu® Molnupiravir 200mg Capsule is an antiviral medicine. It works by inhibiting the SARS-CoV-2 virus from replicating. This stops the virus from producing new copies and hence decreases the viral load in the body.

Size: 40 Capsules
Brand name: Lagevrio
Title Range Discount
Items: 2 - 4 5%
Items: 5 - 8 10%
Items: 9 + 15%

Description

What is Cipmolnu® Molnupiravir 200mg Capsules?

With the spread of the COVID-19 global pandemic since 2019, the entire world worked towards introducing anti-virus vaccines. Further, into research, it was able to produce oral antiviral medication to treat the virus.

Cipmolnu® Molnupiravir 200mg Capsule (Lagevrio Generic) is one of the pioneers of oral medicine introduced to public use on December 28, 2021, as a treatment for the Sars-CoV-2 virus. It was given an emergency use approval from the Indian Drug Regulation authorities, which is now approved by the U.S Food and Drug Administration (FDA).

Cipmolnu® Molnupiravir 200mg Capsule helps prevent the replication of the virus within the body, thereby reducing the viral capacity and severity of the disease. The drug can be used to treat adults affected by COVID-19 during mild to moderate stages of symptoms. Also, the patients at high risk of disease complications are included in the criteria.

Cipmolnu® Molnupiravir 200mg Capsule is only indicated in patients with mild to moderate COVID-19 symptoms and who have a high risk of developing severe symptoms. The risk factors include obesity, older age (>60 years), diabetes mellitus, and heart diseases. It is not indicated in patients who require immediate hospitalization due to COVID-19. This drug has also been approved by the U.S. Food and Drug Administration (FDA) and the UK regulatory agency for emergency use.

Cipmolnu® Molnupiravir 200mg Capsule should be taken orally for no longer than 5 consecutive days. It is important to complete the entire 5 days of treatment, therefore do not stop taking it even if you feel better. The medicine may cause dizziness, headache, diarrhea, and nausea in some patients. If one experiences any such side effects, discuss them with the doctor. They may help with the treatment or suggest ways to prevent them.

Before taking Cipmolnu® Molnupiravir 200mg Capsule, let the doctor know if you have any pre-existing medical conditions. To make sure it is safe for you, inform your doctor about all the other medications you are taking. The use of Cipmolnu® Molnupiravir 200mg Capsule is not recommended in pregnant women. Pregnant and breastfeeding women should consult with their doctors before taking this medicine.


How to use Molnupiravir 200mg Capsules?

The capsule should be taken orally for 5 or less consecutive days. The 5-day consistency is essential for the best results. Therefore, the treatment should not cease even the condition positively improves. However, if you miss a dose, please inform your doctor.

Before using Cipmolnu® Molnupiravir 200mg Capsule, please discuss the pre-existing medical conditions and the other ongoing medications during the time of Cipmolnu treatment with a medical doctor. The capsule is safe for patients with Kidney and Liver related diseases.

As the capsule contains risk factors such as obesity, diabetes mellitus, and heart-related issues, it is recommended to be guided by the medical professional regarding Do’s and Don’ts.
Patients may experience the side effects listed below. Therefore, keep your doctor informed as they suggest methods to reduce or prevent the side effects.

If you are pregnant or a breastfeeding woman, Cipmolnu® Molnupiravir 200mg Capsule is not recommended to use. Animal studies have shown potential risks to the developing fetus. Therefore, it is mandatory to consult the doctor before medication.


Side effects Molnupiravir 200mg

As per research evidence, the side effects do not include fatal complications nor require any medical observation. Majority of the side effects dimmish as the body gets used to the medicine. However, if the side effects persist or if you have any personal concerns, contact your doctor immediately. Some common side effects are headache, nausea, dizziness, diarrhea.

Taking Cipmolnu® Molnupiravir 200mg Capsule along with medicines such as Abamune Tablet, A-Bec Tablet, Virol 300mg Tablet, Adfovir 10mg Tablet, Adheb 10mg Tablet, Virosine DR 250mg/400mg Capsule can cause life-threatening side effects. Not only the listed drugs, but there is a long list of interactive drugs. Therefore, medical assistance before starting the Cipmolnu® Molnupiravir 200mg Capsule is a must.

Cipmolnu® Molnupiravir 200mg Capsule is one of the best alternatives for patients who have not been vaccinated against COVID-19. It is reported to have shown positive results in unvaccinated patients.

Reviews

There are no reviews yet.

Be the first to review “Cipmolnu® Molnupiravir Capsules”

Your email address will not be published.